Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: A randomized, controlled, proof-of-concept study

Angiology

Volumn 58, Issue 6, 2008, Pages 710-716

  Schindler, Christoph ^a   Mueller, Axel ^b   Bramlage, Peter ^a   Boecking, Wolfgang ^a   Kirch, Wilhelm ^a   Schweizer, Johannes ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; QUINAPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BIOASSAY; CLAUDICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; HUMAN; MALE; MORNING DOSAGE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STENT; SUPERFICIAL FEMORAL ARTERY; TREADMILL ERGOMETRY; ANKLE; BLOOD PRESSURE; BRACHIAL ARTERY; COMPARATIVE STUDY; CONVALESCENCE; ECHOGRAPHY; FEMORAL ARTERY; HOSPITALIZATION; INSTRUMENTATION; INTERMITTENT CLAUDICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VASCULARIZATION; WALKING;

AGED; ANGIOPLASTY, BALLOON; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE; ARTERIAL OCCLUSIVE DISEASES; BENZIMIDAZOLES; BLOOD PRESSURE; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RECURRENCE; SEVERITY OF ILLNESS INDEX; STENTS; TETRAHYDROISOQUINOLINES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 38049048355     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319707305962     Document Type: Article

References (39)

1. Dormandy JA, Rutherford RB: Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31: S1 - S296, 2000.
2. Capek P., McLean GK, Berkowitz HD: Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 83: 170-80, 1991.
3. Cejna M., Thurnher S., Illiasch H.,, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 12: 23-31, 2001.
4. Zdanowski Z., Albrechtsson U., Lundin A.,, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol 18: 251-255, 1999.
5. Huber KC, Schwartz RS, Edwards WD,, et al. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am Heart J 125: 695-701, 1993.
6. Kawamura M., Terashita Z., Okuda H.,, et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 266: 1664-1669, 1993.
7. Miyazaki M., Wada T., Shiota N., Takai S.: Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 13 Suppl 1: S21-25, 1999 ; discussion S33 - S34.
8. Powell JS, Clozel JP, Muller RK,, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186-188, 1989.
9. Ohtani K., Egashira K., Ihara Y.,, et al. Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells. Hypertension 48: 664-670, 2006.
10. Pratt RE, Dzau VJ: Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 93: 848-852, 1996.
11. Cheng ZJ, Vapaatalo H., Mervaala E.: Angiotensin II and vascular inflammation. Med Sci Monit 11: RA194-205, 2005.
12. Forrester JS, Fishbein M., Helfant R., Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17: 758-769, 1991.
13. Mercator Study Group: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 86: 100-110, 1992.
14. Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 25: 362-369, 1995.
15. MacMahon S., Sharpe N., Gamble G.,, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 36: 438-443, 2000.
16. Cashin-Hemphill L., Holmvang G., Chan RC, Pitt B., Dinsmore RE, Lees RS: Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. Am J Cardiol 83: 43-47, 1999.
17. Peters S., Gotting B., Trummel M., Rust H., Brattstrom A.: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 13: 93-97, 2001.
18. Yoshida O., Hirayama H., Nanasato M., Watanabe T., Murohara T.: The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 149: e2, 2005.
19. Schindler C., Schweizer J., Mueller A.,, et al. Candesartan Treatment for Peripheral Occlusive Arterial Disease after Stent Angioplasty: A Randomised, Placebo-Controlled Trial. Clin Drug Invest 25: 89-97, 2005.
20. Schweizer J., Kirch W., Koch R., Hellner G., Uhlmann K. Effect of high dose verapamil on restenosis after peripheral angioplasty. J Am Coll Cardiol 31: 1299-1305, 1998.
21. Clozel JP, Hess P., Michael C., Schietinger K., Baumgartner HR: Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension 18 (4 Suppl). 1155-59, 1991.
22. Wilson DP, Saward L., Zahradka P., Cheung PK: Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 42: 761-772, 1999.
23. Nozawa Y., Matsuura N., Miyake H., Yamada S., Kimura R.: Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Life Sci 64: 2061-2070, 1999.
24. Seeger H., Wallwiener D., Mueck AO: Class-specific inhibition of angiotensin II-induced proliferation of human smooth muscle cells by AT1-antagonists. Atheroscler Suppl 2: 148, 2001.
25. Khaper N., Singal PK: Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 37: 1461-1466, 2001.
26. Wakeyama T., Ogawa H., Iida H.,, et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 67: 519-524, 2003.
27. Rakugi H., Wang DS, Dzau VJ, Pratt RE: Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 90: 449-455, 1994.
28. Vink A., Schoneveld AH, Borst C., Pasterkamp G.: The contribution of plaque and arterial remodeling to de novo atherosclerotic luminal narrowing in the femoral artery. J Vasc Surg 36: 1194-1198, 2002.
29. Garcia LA: Stenting the chronic totally occluded superficial femoral artery: endovascular clinical benefit. J Invasive Cardiol 18: 322-323, 2006.
30. Ferrario CM, Strawn WB: Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128, 2006.
31. Hoffmann R., Mintz GS, Dussaillant GR,, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94: 1247-1254, 1996.
32. Kornet L., Hoeks AP, Lambregts J., Reneman RS: In the femoral artery bifurcation, differences in mean wall shear stress within subjects are associated with different intima-media thicknesses. Arterioscler Thromb Vasc Biol 19: 2933-2939, 1999.
33. Stoll M., Steckelings UM, Paul M., Bottari SP, Metzger R., Unger T.: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651-657, 1995.
34. Donoghue M., Hsieh F., Baronas E.,, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-9, 2000.
35. Tipnis SR, Hooper NM, Hyde R., Karran E., Christie G., Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
36. Crackower MA, Sarao R., Oudit GY,, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828, 2002.
37. Schindler C., Brosnihan KB, Ferrario CM,, et al. Comparison of Inhibitory Effects of Irbesartan and Atorvastatin Treatment on the Renin Angiotensin System (RAS) in Veins: A Randomized Double-Blind Crossover Trial in Healthy Subjects. J Clin Pharmacol 47: 112-120, 2007.
38. Langeveld B., van Gilst WH, Tio RA, Zijlstra F., Roks AJ: Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45: 138-141, 2005.
39. Schindler C., Bramlage P., Kirch W., Ferrario CM: Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 3: 125-137, 2007.